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Purpose: The effect of different peritoneal dialysis (PD) modalities on the decline in 
residual renal function (RRF) is unclear due to inconsistencies among studies. In par-
ticular, the effect of automated peritoneal dialysis (APD) modalities [continuous cy-
clic peritoneal dialysis (CCPD) and nightly intermittent peritoneal dialysis (NIPD)] 
on RRF has not been examined in a large cohort. Materials and Methods: We con-
ducted a single-center retrospective study to investigate the association between PD 
modalities and decline in RRF in 142 incident PD patients [34 on CCPD, 36 on 
NIPD, and 72 on continuous ambulatory peritoneal dialysis (CAPD)]. RRF was 
measured within 2 months from PD start and at 1 year after PD initiation. Results: 
The RRF at 1 year after PD initiation was 1.98±2.20 mL/min/1.73 m² in CCPD 
patients and 3.63±3.67 mL/min/1.73 m² in NIPD patients, which were moderately 
lower than 4.23±3.51 mL/min/1.73 m² in CAPD patients (p=0.064). Moreover, 
there was no significant difference in the 1-year rate of decline of RRF between 
CCPD and NIPD patients, although APD patients had a faster 1-year RRF decline 
rate than CAPD patients (CCPD and NIPD vs. CAPD: -45.68 and -36.69 vs. 
1.17%/year, p=0.045). APD was associated with a more rapid decline in RRF in 
patients with end-stage renal disease undergoing PD, although multivariate analy-
sis attenuated the significance of this finding (β=-31.50; 95% CI, -63.61 to 0.62; 
p=0.052). Conclusion: Our results suggest that CAPD might be more helpful than 
APD for preserving RRF during the first year of dialysis therapy, although there 
was no significant difference in the 1-year rate of decline of RRF between the two 
APD modalities.
Key Words:   Continuous ambulatory peritoneal dialysis, end-stage kidney disease, 
glomerular filtration rate, peritoneal dialysis
INTRODUCTION
Residual renal function (RRF) in dialysis patients is clinically important because it 
is clearly associated with better overall health, well-being, and survival.1-5 RRF 
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excluded patients who were younger than 18 years of age, 
patients who did not undergo serial urea kinetic studies in-
cluding measurement of RRF, patients who had residual 
urine volume <100 mL/day, and patients who changed 
their PD modality during the first year of therapy. Accord-
ing to the study protocol, a total of 142 clinically stable pa-
tients (34 on CCPD, 36 on NIPD, and 72 on CAPD) were 
finally eligible.
The study protocol was approved by the Institutional Re-
view Board (IRB) of YUHS Clinical Trial Center. Howev-
er, because this study was a retrospective medical record-
based study and the study subjects were de-identified, the 
IRB waived the need for written consent from the patients.
Dialysis prescription
CAPD patients received four exchanges per day, routinely 
with 2.0 L dialysate. APD patients received 4 to 5 exchang-
es during an 8- to 10-hour night-time dwell with 2.0 L of 
instilled volume, using a cycler (Home Choice APD system 
ver. 10.4, Baxter). CCPD patients had one or two additional 
2.0 L exchanges daily, whereas NIPD patients had an emp-
ty peritoneal cavity during the daytime. In the present study, 
all patients were prescribed to achieve the target of weekly 
Kt/V urea >1.7, which is the minimal target of dialysis dose 
for PD patients.
Data collection
Demographic and clinical data at the time of PD initiation, 
including age, gender, comorbidities, and primary kidney 
disease were reviewed from medical records. The modified 
Charlson Comorbidity Index-a composite score of age and 
multiple comorbid conditions-was used to assess the bur-
den of chronic disease.20 RRF was assessed as an average 
of 24-hour urine urea and creatinine clearance measured 
within 2 months of beginning PD and at 1 year. RRF was 
normalized to 1.73 m2 body surface area and expressed as 
mL/min/1.73 m2. Changes in RRF during the follow-up pe-
riod [1-year rate of decline of RRF (%)] were calculated as 
follows:
1-year rate of decline of RRF (%)=
RRF at baseline-RRF after 1 year
×100
                                                                RRF at baseline
According to this calculation, a higher 1-year RRF decline 
rate (%) means a faster decline in RRF after PD initiation. 
Adequacy of PD was estimated at the same time-points by 
measuring weekly total Kt/V for urea. The standard peritone-
contributes not only to salt and water removal, but also the 
clearance of small and medium-sized molecular weight ure-
mic toxins. Because medium-sized molecular weight uremic 
toxins are not readily removed by dialysis, preservation of 
RRF is an important issue for patients with end-stage renal 
disease (ESRD) to prevent uremic symptoms and signs, in-
cluding pruritus, inflammation, and mineral bone disorders. 
Furthermore, RRF is associated with better preservation of 
renal endocrine and metabolic function and superior volume 
homeostasis.6 Therefore, determining the risk factors associ-
ated with a decline in RRF has become an important re-
search subject.
Some previous studies have reported that RRF is better 
preserved in patients on continuous ambulatory peritoneal 
dialysis (CAPD) than on hemodialysis.7-9 Moreover, CAPD 
has been reported to preserve RRF better than automated 
peritoneal dialysis (APD),10-13 however, other studies did not 
find a significant difference in the rate of decline of RRF 
when they compared the two peritoneal dialysis (PD) mo-
dalities.14-19
The use of APD has increased substantially over the last 
few years, driven primarily by improvements in cyclers and 
patients preferring to be able to perform relatively liberal 
daytime activities. Within APD two modalities can be cho-
sen: continuous cyclic peritoneal dialysis (CCPD) and 
nightly intermittent peritoneal dialysis (NIPD). Therefore, 
the influence of dialysis modality on RRF should also be 
considered when to decide which APD modality to adopt. 
However, no study has compared the effect of APD modal-
ities on RRF. Thus, we conducted this single-center retro-
spective study to investigate whether there were significant 
differences in the 1-year rate of decline of RRF according 
to the PD modalities, of CCPD, NIPD, and CAPD.
MATERIALS AND METHODS
　　　
Patients
We reviewed the medical records for incident PD patients 
who were treated in the Yonsei University Health System 
(YUHS) between January 2000 and March 2011. In the 
absence of specific clinical indications, patients were al-
lowed to select the modality of PD, after being fully in-
formed about each of the PD modalities. A patient’s prefer-
ence or need to be relatively free to perform the activities 
of daily living during the daytime was a major determinant 
for starting dialysis therapy with APD in most cases. We 
Effect of PD Modalities on Residual Renal Function
Yonsei Med J   http://www.eymj.org   Volume 55   Number 1   January 2014 143
for categorical variables. Pearson’s correlation analysis was 
performed to elucidate the relationships between the rate of 
decline in RRF and other variables. In addition, risk factors 
assumed to be associated with a rapid rate of decline of 
RRF were evaluated using multivariate analysis. A p-value 
of <0.05 was considered statistically significant.
RESULTS
 
Patient characteristics
The baseline demographic, clinical, and biochemical charac-
teristics of the patients are shown in Table 1. Age, gender, 
body mass index (BMI), mean arterial pressure, and biochem-
ical parameters were similar among the three groups. Com-
pared with patients on CAPD and CCPD, patients on NIPD 
al equilibrium test, described by Twardowski21 was also per-
formed at the same time to estimate peritoneal transport 
characteristics and all subjects were categorized into four 
groups according to the value of 4-hour dialysate-to-plasma 
creatinine ratio (4-h D/P cr) as follows: high, ≥0.81; high 
average, 0.65 to 0.80; low average, 0.50 to 0.64; low <0.50. 
Laboratory tests results and the incidence of peritonitis 
were also collected.
Statistical analyses
Statistical analyses were performed using SPSS for win-
dows version 19.0 (SPSS Inc., Chicago, IL, USA). Contin-
uous variables are expressed as means±standard deviations 
and categorical variables as numbers with percentages. 
Baseline characteristics of the groups were compared using 
one-way ANOVA for continuous variables and the χ2 test 
Table 1. Baseline Demographic, Clinical, and Biochemical Characteristics at the Time of PD Initiation
Variable CCPD (n=34) NIPD (n=36) CAPD (n=72) p value
Age (yrs)   46.3±13.9   49.2±11.5   53.0±11.8 0.150
Male (n, %) 23 (67.6) 21 (58.3) 39 (54.2) 0.673
Body mass index (kg/m²) 23.6±3.7 23.4±3.5 23.9±3.4 0.892
Mean arterial pressure (mm Hg)   97.9±11.9   95.6±10.4 95.6±9.4 0.726
Modified Charlson Comorbidity Index   4.4±2.7   4.3±2.2   4.5±2.5 0.813
Cardiovascular comorbidities (n, %)*   8 (23.5)   4 (11.1) 21 (29.2) 0.194
LVH on ECG (%) 18 (52.9) 16 (44.4) 32 (44.4) 0.807
Primary kidney disease (n, %) 0.063
    Diabetes mellitus   8 (23.5) 13 (36.1) 39 (54.1)
    Hypertension 12 (35.3) 11 (30.5) 12 (16.7)
    Glomerulonephritis   5 (14.7) 10 (27.8) 4 (5.6)
    Others   9 (26.5) 2 (5.6) 17 (23.6)
Medication use (n, %)
    RAS blockers 22 (64.7) 25 (69.4) 55 (76.4) 0.752
    Diuretics 18 (52.9) 19 (52.8) 39 (54.2) 0.894
Hemoglobin (g/dL) 10.0±1.5   9.9±1.5 10.4±1.1 0.313
Blood urea nitrogen (mg/dL)   48.8±14.4   54.1±19.8   46.3±13.3 0.195
Creatinine (mg/dL)   7.4±2.9   7.0±2.0   6.8±2.5 0.203
Albumin (g/dL)   3.4±0.6   3.4±0.5   3.4±0.5 0.137
Total cholesterol (mg/dL) 159.0±37.3 172.6±39.4 161.7±36.3 0.485
Residual renal function (mL/min/1.73 m²)  3.53±2.83 (2.57)† 5.31±3.09 (4.44)†  4.61±2.54 (3.79)† 0.149
Urine volume (mL/day) 907.8±573.4 (580)†  1363.7±1017.9 (1075)† 966.2±513.1 (805)† 0.079
Weekly Kt/V urea   2.13±0.57   2.26±0.52   2.49±0.63 0.109
4-hr dialysate-to-plasma creatinine ratio   0.71±0.18   0.77±0.14   0.78±0.09 0.652
High transporter (n, %)   9 (26.5) 3 (8.3) 20 (27.8) 0.071
Peritonitis rate (episodes/patient-yrs) 0.18 0.06 0.21 0.190
PD, peritoneal dialysis; CAPD, continuous ambulatory peritoneal dialysis; CCPD, continuous cyclic peritoneal dialysis; NIPD, nightly intermittent peritoneal 
dialysis; LVH on ECG, left ventricular hypertrophy on electrocardiogram; RAS, renin-angiotensin system.
Data are presented as means±SDs or as numbers (percentages). 
*Cardiovascular comorbidities were defined as coronary artery disease, cerebrovascular disease, peripheral artery disease, and congestive heart failure.
†Median value.
Chan Ho Kim, et al.
Yonsei Med J   http://www.eymj.org   Volume 55   Number 1   January 2014144
ter initiation of dialysis according to PD modality. The RRF 
at 1 year after PD initiation was 1.98±2.20 mL/min/1.73 m² 
in CCPD patients and 3.63±3.67 mL/min/1.73 m² in NIPD 
patients; these values were moderately lower than the aver-
age value of 4.23±3.51 mL/min/1.73 m² in CAPD patients 
(p=0.064). There was no significant difference in the rate of 
decline of RRF between the two APD groups, but the APD 
groups displayed a faster 1-year rate of decline of RRF than 
the CAPD group (CCPD and NIPD vs. CAPD: -45.68 and 
-36.69 vs. 1.17%/year, p=0.045 in Fig. 2). However, there 
was no significant difference in the 1-year decline rate of 
urine volume among the three groups (CCPD vs. NIPD vs. 
CAPD: -20.03 vs. 16.14 vs. -30.91%/year, p=0.195 in Fig. 
3). Patients who lost all of their RRF during follow-up peri-
od were 6 (17.6%) in CCPD patients, 3 (8.3%) in NIPD pa-
tients, and 4 (5.6%) in CAPD patients (p=0.325). On the 
contrary, patients who showed any increase in their RRF 
tended to have higher urine volume at the time of PD initia-
tion, although this difference did not reach statistical signifi-
cance. In patients with primary kidney disease, a higher 
proportion of patients in the CAPD group had diabetes, al-
though the difference was not statistically significant. Time-
average HbA1c levels of diabetic patients during follow-up 
period were also comparable among the three groups (CCPD 
vs. NIPD vs. CAPD: 7.3±0.2 vs. 7.1±0.6 vs. 7.3±0.7%, 
p=0.717). There were no significant differences in baseline 
RRF, weekly Kt/V urea, 4-h D/P cr, and biochemical param-
eters among the three groups. Moreover, the incidence of 
peritonitis was not significantly different among the three 
groups during the follow-up period.
Decline in residual renal function and urine volume 
from baseline to 1 year after PD initiation
Fig. 1 shows the changes in RRF from baseline to 1 year af-
Fig. 1. Decline of residual renal function in CCPD patients (A), NIPD patients (B), and CAPD patients (C) from baseline to 1-year after PD initiation. CCPD, con-
tinuous cyclic peritoneal dialysis; NIPD, nightly intermittent peritoneal dialysis; CAPD, continuous ambulatory peritoneal dialysis; PD, peritoneal dialysis.
Fig. 2. Comparison of the 1-year rate of decline of residual renal function 
among the three groups.*vs. CAPD group, p<0.05. CCPD, continuous cyclic 
peritoneal dialysis; NIPD, nightly intermittent peritoneal dialysis; CAPD, con-
tinuous ambulatory peritoneal dialysis. 
Fig. 3. Comparison of the 1-year rate of decline of urine volume among the 
three groups. CCPD, continuous cyclic peritoneal dialysis; NIPD, nightly in-
termittent peritoneal dialysis; CAPD, continuous ambulatory peritoneal dial-
ysis.
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to preserve RRF as long as possible after the initiation of 
dialysis. To date, several risk factors, such as male gender, 
diabetes, uncontrolled hypertension, and heavy proteinuria, 
have been demonstrated to be associated with a rapid de-
cline in RRF.7,17,19,22 Despite the importance of preserving 
RRF, the influence of PD modalities on RRF after the initi-
ation of PD therapy remains unclear because of inconsis-
tencies among the studies that may have been arisen due to 
the diverse experimental designs and different study popu-
lations. In particular, little is known about the effect of the 
APD modalities of CCPD and NIPD on the decline in RRF.
In the present study, we enrolled clinically stable incident 
patients in order to analyze the inherent influence of each 
PD modality on RRF, and found that RRF declined signifi-
cantly faster in incident APD (CCPD and NIPD) patients 
than CAPD patients during the first year after the initiation 
of PD and that APD modality was associated with a more 
rapid decline in RRF in patients with ESRD undergoing 
PD, although multivariate analysis attenuated the signifi-
cance of this finding. These results are consistent with those 
of several previous studies.10-13 Hiroshige, et al.10 assorted 
patients into three groups according to PD modality (CCPD, 
NIPD, and CAPD) and analyzed the rate of decline of RRF 
in each group. Recently, Michels, et al.12 stated that the risk 
of losing all RRF was higher in patients starting dialysis on 
APD than those starting on CAPD, especially in the first 
year. Although the results of these previous studies were sim-
ilar to ours, Hiroshige, et al.10 included only a small number 
of patients (5 on CCPD, 8 on NIPD, and 5 on CAPD), and 
CCPD and NIPD groups were not compared in the latter 
study. We compared the rate of decline of RRF between 
two APD modalities in a relatively large number of pa-
tients, and confirmed that there was no significant differ-
ence in the 1-year rate of decline of RRF between the two 
were 4 (11.8%) in CCPD patients, 7 (19.4%) in NIPD pa-
tients, and 29 (40.3%) in CAPD patients (p=0.004).
Predictors of rapid decline of residual renal function
The rate of decline of RRF was negatively correlated with 
APD modality (APD vs. CAPD; r=-0.286, p=0.014) and 
baseline urine volume (r=-0.244, p=0.036) in univariate 
analysis. When patients were divided into two groups ac-
cording to the median value of baseline RRF (3.6 mL/
min/1.73 m2), there was no significant difference in the rate 
of decline of RRF between the two groups (>3.6 mL/min/ 
1.73 m2 vs. ≤3.6 mL/min/1.73 m2: -14.64 vs. -28.60%/year, 
p=0.435). Moreover, the rates of decline of RRF were not 
significantly different in patients with diabetes compared 
with those without diabetes (DM vs. non-DM: -15.57 vs. 
-21.31%/year, p=0.210). On multivariate linear regression 
analysis using the known risk factors of rapid decline of 
RRF, including age, gender, DM, BMI, albumin, peritonitis 
episode, baseline RRF, baseline urine volume, and APD vs. 
CAPD, we found that the choice of APD (vs. CAPD) (β= 
-31.50; 95% CI, -63.61 to 0.62; p=0.052) and baseline urine 
volume (β=-0.51; 95% CI, -1.06 to 0.05; p=0.061) were 
marginally associated with a rapid rate of decline of RRF 
(Table 2).
DISCUSSION
RRF plays a major role in maintaining water and electro-
lyte balance, in maintaining erythropoietin synthesis and 
converting vitamin D to its active form, and in eliminating 
so-called middle molecules.2,4,5 RRF has therefore been rec-
ognized as a significant predictor of morbidity and mortali-
ty in patients with ESRD on dialysis,1-6 and it is important 
Table 2. Multiple Linear Regression Analysis of Variables Affecting the 1-Year Decline Rate of RRF
Variables β 95% CI p value
Age (yrs) -1.40   -2.96 to 0.17 0.089
Male (versus female) -1.24   -36.71 to 34.28 0.946
DM (versus non-DM) 32.01     -6.82 to 70.85 0.105
Body mass index (kg/m2)   3.39   -2.03 to 8.80 0.217
Albumin (g/dL) 18.99   -16.66 to 54.64 0.292
Peritonitis episode  -4.37   -52.43 to 43.69 0.857
Baseline RRF (mL/min/1.73 m²)    0.08   -7.54 to 7.69 0.984
Baseline urine volume (mL/day)   -0.51   -1.06 to 0.05 0.061
APD (CCPD and NIPD) vs. CAPD -31.50 -63.61 to 0.62 0.052
RRF, residual renal function; DM, diabetes mellitus; APD, automated peritoneal dialysis; CCPD, continuous cyclic peritoneal dialysis; NIPD, nightly intermit-
tent peritoneal dialysis; CAPD, continuous ambulatory peritoneal dialysis.
For the model, the adjusted R²=0.145, p=0.014.
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who have sufficient urine volume and RRF. However, after 
adjustment for other variables, a moderate association re-
mained, suggesting that baseline urine volume may in fact 
determine the rate of decline of RRF. It can be surmised 
that patients with low urine volume at the beginning of PD 
therapy are unlikely to experience as much of a decrease in 
RRF as patients with a high urine volume.
APD has been suggested to have advantage over CAPD 
with respect to the incidence of peritonitis, mainly due to the 
low number of connections required during the daytime.31-34 
The result of our study did not demonstrate the superiority 
of APD to CAPD in reducing episodes of peritonitis, which 
might be due to our relatively short follow-up period.
Our present study has several limitations. First, diabetes 
mellitus, as the primary kidney disease, was more predomi-
nant in the CAPD group than the other groups, although 
this difference was not statistically significant. In the litera-
ture, diabetes has been shown to have a negative influence 
on the preservation of RRF in ESRD patients.7,17,22 There-
fore, the rate of decline of RRF in diabetic patients might be 
different from that of patients with other causes of ESRD. 
However, when subgroup analysis was performed accord-
ing to the presence of diabetes mellitus, there were similar 
trends in the 1-year rate of decline of RRF among the three 
groups (DM group, CCPD vs. NIPD vs. CAPD: -39.57 vs. 
-11.49 vs. 15.92%/year, p=0.057; non-DM group, CCPD 
vs. NIPD vs. CAPD: -51.71 vs. -58.76 vs. -11.54%/year, p= 
0.012). Second, the use of biocompatible PD solution was 
not examined. In recent years, it has been suggested that bio-
compatible PD solutions can result in better preservation of 
RRF.35-39 However, conflicting results have also been report-
ed, and the clinical benefits of biocompatible PD solutions 
have not yet been fully established.40,41 Third, the follow-up 
duration of our study was 12 months, which is relatively 
shorter than other studies.4,12,42 Given that PD patients dis-
play diverse patterns of decline in RRF, a longer period of 
observation is required to validate our findings. Finally, the 
retrospective observational study design is critical limita-
tion. However, because the choice of PD modality is based 
primarily on the patient’s preference, randomization for di-
alysis is very difficult, and this limitation is unlikely to be 
resolved completely in studies of PD patients. Despite all 
inherent drawbacks, our single-center study included more 
CCPD and NIPD patients than previous studies, giving us 
more statistical power.
In conclusion, we demonstrated that RRF declined more 
rapidly in patients who started dialysis on APD (CCPD and 
APD modalities. After 1-year follow-up, 40 (28.2%) pa-
tients presented an improvement of RRF (4 in CCPD, 7 in 
NIPD, and 29 in CAPD group). Among these, 6 patients 
showed more than 2-fold increase in RRF. Although partial 
recovery of RRF in dialysis patients was reported in previ-
ous studies,23-25 the underlying mechanism remains unclear.
It is not yet completely understood how APD detrimental-
ly affects RRF. Previous studies have shown that changes in 
body fluid status are related to a rapid decline of RRF in di-
alysis patients.26-30 In APD, most ultrafiltration occurs during 
an 8-hour period at night, a relatively short-time period, com-
pared to CAPD. The intermittent nature of the APD modali-
ty may result in greater variations in hemodynamic status 
and possibly cause ischemia, which could exacerbate the 
decline of RRF. Similarly, Hufnagel, et al.11 suggested that 
the accelerated decline in RRF in the APD group was due 
to acute changes in osmotic loading and volume removal. 
In the present study, however, we were not able to confirm 
this hypothesis, although we expected that the more inter-
mittent nature of NIPD might result in a greater decline in 
RRF. Our results might have been affected by the possible 
process of information censoring. Because patients who 
changed their initial dialysis modality within the first year 
were excluded from the analysis, it is possible that if the 
initial dialysis modality caused a rapid decline in RRF, ear-
ly dropout could have occurred, resulting in selection bias. 
Therefore, further prospective studies are needed to confirm 
our findings.
A few observational studies reported that a higher RRF at 
the time of PD initiation was associated with more rapid de-
cline in RRF during the follow-up period, although the pa-
tients with a higher RRF took a longer time to develop com-
plete anuria.9,17,18 In our study, we did not find a relationship 
between higher RRF at the time of PD initiation and a rapid 
decline in RRF. Actually, we divided patients into two groups 
according to the median value of baseline RRF (>3.6 mL/
min/1.73 m2 vs. ≤3.6 mL/min/1.73 m2) and compared the 
rate of decline of RRF. There was no significant difference in 
the rate of decline of RRF between the two groups. When 
further subgroup analysis was performed in each PD modali-
ty group, the results remained unaltered (data not shown). 
However, we did find that RRF declined more rapidly in pa-
tients with a high baseline urine volume, although the sig-
nificance of this finding was attenuated after adjusting for 
other variables. The correlation between baseline urine vol-
ume and a decline of RRF may partially be explained by 
the choice of APD modality, which is preferred by patients 
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